lutetium lu 177 vipivotide tetraxetan,cabazitaxel
emcure,sanofi,novartis
['crpc', 'congrat', 'therap ', 'novartis']
great to see #therap study 3 year results presented at #asco22 by . compelling evidence lu-psma is a new treatment option for people with mcrpc. congrats to all 
The Australian and New Zealand Urogenital and Prostate cancer trials group aims to develop, foster and promote prostate and other urogenital cancer research